Active Ingredient(s): Granisetron
FDA Approved: * December 29, 1993
Pharm Company: * ROCHE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kytril Overview

Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. Granisetron was developed by chemists working at the British dr...

Read more Kytril Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Kytril Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Film, Extended Release: 3.1mg/24hr
  • Injection: (1mg/ml) 1mg/1ml, (1mg/ml) 4mg/4ml, 0.1mg/ml, 0.1mg/ml (0.1mg/ml), 10mg/0.4ml, 1mg, 1mg/ml, 1mg/ml (1mg/ml), 3mg/ml, 4mg/4ml (1mg /ml), 4mg/4ml (1mg/ml)
  • Injection, Extended Release: 10mg/0.4ml (10mg/0.4ml)
  • Solution: 2mg/10ml
  • System: 3.1mg
  • Tablet: 1mg, 2mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Granisetron or a similar ingredient: (3 results)